Mouse Study. Male albino mice weighing 20±1.5 g were fasted from food for 24 hr prior to experiment but were given water ad libitum. Each experimental group consisted of 6 mice. Animals of the different groups were injected intraperitoneally with Safinur in increasing doses of 100-1000 mg/kg body weight. Safinur was applied in concentrations of 1, 5, and 10%; the volume of the solution injected was of the order of 1ml/100g body weight. The animals were observed in the course of seven days. Safinur did not provoke lethality and exerted no toxic effects and thus an LD50 and the toxic doses could not be determined. 

Cat Study. The active ingredient in Safinur was injected intravenously to five cats in doses of 10, 20, 30, 40 and 50 mg/kg. No short or long-term toxicity was noticed. 

Rat Study. Three groups of ten male Wistar rats weighing 250-300g received intravenous injections of the active ingredient in Safinur of 10, 20 and 30 mg/kg. No acute or long-term toxicity was observed. 

Rabbit Study. Twenty four rabbits weighing between 2 and 2.5 kg were divided in 3 groups, each receiving 10, 20 or 30 mg/kg of the active ingredient in Safinur intravenously. No acute or long-term toxicity was observed. 

Dog Study. Four male dogs weighing 27, 26, 19 and 19 kg were given the active ingredient in Safinur at 10 and 30 mg/kg in a volume of 0.3 ml/kg into vein sephina of one of the hind legs. Two dogs had no signs of toxicity. One of the dogs vomited 75 min. after the injection. Another showed signs of allergic reaction (itching, red eyes) which disappeared within 1.5- 2 hrs. No long-term effects were observed. 

Although Safinur can be considered relatively non-toxic, the above studies do not constitute definitive evidence of its lack of toxicity in humans. Safinur is currently under study and a more definitive toxicity profile in humans should be available in the near future.